Active Oncology Clinical Trials

This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can decide if a specific medicine is the correct treatment for a particular patient or whether enrollment in a clinical trial is appropriate. If you have questions about treatment of your medical condition, consult a qualified healthcare professional.

Clinical Trials

Active Oncology Clinical Trials

BOLSTER: Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating certepetide in combination with standard-of-care versus standard-of-care alone in subjects with first-line and second-line cholangiocarcinoma (bile duct cancer) in the United States

ASCEND: Phase 2b randomized, double-blind study of certepetide for the treatment of metastatic pancreatic ductal adenocarcinoma in Australia and New Zealand

CENDIFOX: Phase 1b/2 open-label study of certepetide for the treatment of pancreatic, colon, and appendiceal cancers in the United States

Phase 1b/2 open-label study of certepetide for the treatment of metastatic pancreatic ductal adenocarcinoma in China

iLSTA: A Phase 1 single-blind study evaluating certepetide in combination with durvalumab, gemcitabine and nab-paclitaxel as a first-line treatment in locally advanced pancreatic ductal adenocarcinoma (PDAC) in Australia

Phase 2a proof-of-concept, double-blind, placebo-controlled, randomized study evaluating certepetide when added to standard of care (temozolomide) versus SoC alone and placebo in subjects with newly diagnosed Glioblastoma Multiforme in Estonia and Latvia

Phase 2b, double-blind, placebo-controlled, randomized, multicenter study evaluating certepetide (also known as LSTA1 or CEND-1) and chemotherapy in locally advanced unresectable metastatic pancreatic ductal adenocarcinoma in China